 |
|
|
| |
Response to 3 DAAs + RBV by Patient Characteristics: INTERFERON-FREE REGIMENS OF ABT-450/r,
ABT-267, ABT-333, AND RIBAVIRIN ACHIEVE HIGH SUSTAINED VIROLOGIC RESPONSE 12
WEEKS POST-TREATMENT (SVR12) RATES IN PATIENTS WITH CHRONIC HCV GENOTYPE 1
REGARDLESS OF RACE, ETHNICITY, OR OTHER BASELINE CHARACTERISTICS
|
| |
| |
Reported by Jules Levin
Digestive Disease Week (DDW) 2013
Orlando, FL, May 20, 2013
Maribel Rodriguez-Torres1, Frederick A. Nunes2, Daniel E. Cohen3, Wangang
Xie3, Christal Marincic3, Amit Khatri3, Tami Pilot-Matias3, Thomas Podsadecki3, and Barry Bernstein3
1: Fundación de Investigación de Diego, San Juan, PR, 2: Univeristy of
Pennsylvania Health System, Philadelphia, PA, 3: AbbVie Inc., North Chicago, IL
|
| |
|
|
|
|
|
